Aetion has signed a research collaboration agreement with the U.S. Food and Drug Administration (FDA) to use real-world data to advance the understanding of and response to coronavirus disease (COVID-19).   The research will support FDA objectives to explore the natural history of the disease, as well as treatment and diagnostic patterns, by facilitating the use of relevant, novel data sources and analyzing these data according to well-established principles.   “The FDA is approaching ...